2,931 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Golden State Equity Partners

Golden State Equity Partners acquired a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,931 shares of the medical equipment provider’s stock, valued at approximately $209,000.

A number of other institutional investors have also added to or reduced their stakes in HOLX. AE Wealth Management LLC grew its holdings in Hologic by 23.7% during the 3rd quarter. AE Wealth Management LLC now owns 5,504 shares of the medical equipment provider’s stock worth $382,000 after acquiring an additional 1,056 shares during the last quarter. Czech National Bank grew its holdings in Hologic by 46.9% during the 3rd quarter. Czech National Bank now owns 42,811 shares of the medical equipment provider’s stock worth $2,971,000 after acquiring an additional 13,676 shares during the last quarter. Bfsg LLC grew its holdings in Hologic by 9.4% during the 3rd quarter. Bfsg LLC now owns 19,516 shares of the medical equipment provider’s stock worth $1,354,000 after acquiring an additional 1,681 shares during the last quarter. Trinity Street Asset Management LLP grew its holdings in Hologic by 2.9% during the 3rd quarter. Trinity Street Asset Management LLP now owns 211,225 shares of the medical equipment provider’s stock worth $14,659,000 after acquiring an additional 6,051 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in Hologic by 27.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 74,949 shares of the medical equipment provider’s stock worth $5,201,000 after acquiring an additional 16,319 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

HOLX opened at $75.98 on Monday. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. The company’s fifty day moving average price is $76.03 and its two-hundred day moving average price is $72.82. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $87.88. The company has a market cap of $17.83 billion, a price-to-earnings ratio of 36.01, a PEG ratio of 2.57 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. During the same quarter in the prior year, the company posted $1.07 earnings per share. The business’s revenue was down 5.7% on a year-over-year basis. On average, analysts expect that Hologic, Inc. will post 4.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on HOLX shares. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Evercore ISI upped their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Wednesday, April 10th. Finally, StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $87.00.

Insiders Place Their Bets

In other news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares in the company, valued at $3,670,130.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.